AU2005320352A1 - Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer - Google Patents
Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Download PDFInfo
- Publication number
- AU2005320352A1 AU2005320352A1 AU2005320352A AU2005320352A AU2005320352A1 AU 2005320352 A1 AU2005320352 A1 AU 2005320352A1 AU 2005320352 A AU2005320352 A AU 2005320352A AU 2005320352 A AU2005320352 A AU 2005320352A AU 2005320352 A1 AU2005320352 A1 AU 2005320352A1
- Authority
- AU
- Australia
- Prior art keywords
- lung cancer
- kit
- detecting
- pea
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims 14
- 201000005202 lung cancer Diseases 0.000 title claims 14
- 208000020816 lung neoplasm Diseases 0.000 title claims 14
- 238000000034 method Methods 0.000 title claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 title claims 7
- 238000003556 assay Methods 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 230000002018 overexpression Effects 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000000090 biomarker Substances 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108091093088 Amplicon Proteins 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (63)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53912804P | 2004-01-27 | 2004-01-27 | |
| US53912904P | 2004-01-27 | 2004-01-27 | |
| US60/539,128 | 2004-01-27 | ||
| US60/539,129 | 2004-01-27 | ||
| US58981504P | 2004-07-22 | 2004-07-22 | |
| US60/589,815 | 2004-07-22 | ||
| US60730704P | 2004-09-07 | 2004-09-07 | |
| US60/607,307 | 2004-09-07 | ||
| US62085304P | 2004-10-22 | 2004-10-22 | |
| US62091604P | 2004-10-22 | 2004-10-22 | |
| US62091804P | 2004-10-22 | 2004-10-22 | |
| US62067704P | 2004-10-22 | 2004-10-22 | |
| US62091704P | 2004-10-22 | 2004-10-22 | |
| US62065604P | 2004-10-22 | 2004-10-22 | |
| US62092404P | 2004-10-22 | 2004-10-22 | |
| US62097404P | 2004-10-22 | 2004-10-22 | |
| US62100404P | 2004-10-22 | 2004-10-22 | |
| US62086804P | 2004-10-22 | 2004-10-22 | |
| US62097504P | 2004-10-22 | 2004-10-22 | |
| US62087404P | 2004-10-22 | 2004-10-22 | |
| US60/620,874 | 2004-10-22 | ||
| US60/620,868 | 2004-10-22 | ||
| US60/620,974 | 2004-10-22 | ||
| US60/620,656 | 2004-10-22 | ||
| US60/621,004 | 2004-10-22 | ||
| US60/620,918 | 2004-10-22 | ||
| US60/620,924 | 2004-10-22 | ||
| US60/620,853 | 2004-10-22 | ||
| US60/620,677 | 2004-10-22 | ||
| US60/620975 | 2004-10-22 | ||
| US60/620,906 | 2004-10-22 | ||
| US60/620,917 | 2004-10-22 | ||
| US62105304P | 2004-10-25 | 2004-10-25 | |
| US62113104P | 2004-10-25 | 2004-10-25 | |
| US60/621,053 | 2004-10-25 | ||
| US60/621,131 | 2004-10-25 | ||
| US62817804P | 2004-11-17 | 2004-11-17 | |
| US62810104P | 2004-11-17 | 2004-11-17 | |
| US62812304P | 2004-11-17 | 2004-11-17 | |
| US62815604P | 2004-11-17 | 2004-11-17 | |
| US62818904P | 2004-11-17 | 2004-11-17 | |
| US62811204P | 2004-11-17 | 2004-11-17 | |
| US62813404P | 2004-11-17 | 2004-11-17 | |
| US62825104P | 2004-11-17 | 2004-11-17 | |
| US62811104P | 2004-11-17 | 2004-11-17 | |
| US62814504P | 2004-11-17 | 2004-11-17 | |
| US62816704P | 2004-11-17 | 2004-11-17 | |
| US60/628,189 | 2004-11-17 | ||
| US60/628112 | 2004-11-17 | ||
| US60/628,251 | 2004-11-17 | ||
| US60/628,178 | 2004-11-17 | ||
| US60/628,167 | 2004-11-17 | ||
| US60/628,123 | 2004-11-17 | ||
| US60/628,145 | 2004-11-17 | ||
| US60/628,134 | 2004-11-17 | ||
| US60/628,156 | 2004-11-17 | ||
| US60/628,111 | 2004-11-17 | ||
| US60/628,101 | 2004-11-17 | ||
| US63407504P | 2004-12-08 | 2004-12-08 | |
| US60/634,075 | 2004-12-08 | ||
| US11/051,720 US7569662B2 (en) | 2004-01-27 | 2005-01-27 | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
| US11/051,720 | 2005-01-27 | ||
| PCT/IB2005/004037 WO2006131783A2 (en) | 2004-01-27 | 2005-01-27 | Polynucleotides, polypeptides, and diagnosing lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2005320352A1 true AU2005320352A1 (en) | 2006-08-31 |
| AU2005320352A2 AU2005320352A2 (en) | 2006-08-31 |
| AU2005320352A8 AU2005320352A8 (en) | 2009-04-30 |
Family
ID=37450522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005320352A Abandoned AU2005320352A1 (en) | 2004-01-27 | 2005-01-27 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1774046A4 (enExample) |
| JP (1) | JP2008507261A (enExample) |
| AU (1) | AU2005320352A1 (enExample) |
| CA (1) | CA2555509A1 (enExample) |
| WO (1) | WO2006131783A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005316169B2 (en) | 2004-12-13 | 2011-11-17 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101403019B1 (ko) | 2013-02-25 | 2014-06-03 | 서울대학교산학협력단 | 폐암 진단용 마커 |
| CN114804550B (zh) * | 2022-06-10 | 2023-06-02 | 安徽新宇环保科技股份有限公司 | 一种基于神经网络模型的污水处理调控系统 |
| CN115894942B (zh) * | 2022-11-07 | 2024-01-12 | 同济大学 | 聚己内酯修饰的超支化梳型聚赖氨酸及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2298788A1 (en) * | 1997-08-14 | 1999-02-25 | Novo Nordisk A/S | Antimicrobial composition containing a haloperoxidase, a hydrogen peroxide source, a halide source and an ammonium source |
| US20030170255A1 (en) * | 1999-06-30 | 2003-09-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1343886A2 (en) * | 2000-07-11 | 2003-09-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| AU2002309583A1 (en) * | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU2003234623A1 (en) * | 2002-05-16 | 2003-12-02 | Euro-Celtique, S.A. | Use of gastrin releasing peptide (grp) and its receptor in cancer screening |
-
2005
- 2005-01-27 EP EP05857765A patent/EP1774046A4/en not_active Withdrawn
- 2005-01-27 JP JP2007519922A patent/JP2008507261A/ja active Pending
- 2005-01-27 AU AU2005320352A patent/AU2005320352A1/en not_active Abandoned
- 2005-01-27 CA CA002555509A patent/CA2555509A1/en not_active Abandoned
- 2005-01-27 WO PCT/IB2005/004037 patent/WO2006131783A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005320352A8 (en) | 2009-04-30 |
| AU2005320352A2 (en) | 2006-08-31 |
| JP2008507261A (ja) | 2008-03-13 |
| WO2006131783A2 (en) | 2006-12-14 |
| EP1774046A4 (en) | 2010-09-15 |
| EP1774046A2 (en) | 2007-04-18 |
| WO2006131783A3 (en) | 2009-08-27 |
| CA2555509A1 (en) | 2005-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080020391A1 (en) | Lateral flow methods and devices for detection of nucleic acid binding proteins | |
| JP2005522999A5 (enExample) | ||
| JP2008249727A5 (enExample) | ||
| JP2006500949A5 (enExample) | ||
| RU2009135270A (ru) | Способы выявления воспалительного заболевания кишечника | |
| JP2008509673A5 (enExample) | ||
| CA2999428C (en) | Biomarkers for cervical cancer | |
| JP2017505436A5 (enExample) | ||
| WO1995034650A3 (en) | Mn gene and protein | |
| JP2008502332A5 (enExample) | ||
| JP2004500013A5 (enExample) | ||
| CA2450581A1 (en) | Cardiovascular safety assay | |
| JP2005530515A5 (enExample) | ||
| AU2005320352A1 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer | |
| KR100925147B1 (ko) | 폐암 진단용 마커 | |
| WO2014062069A4 (en) | Shon as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy | |
| JP2005535289A5 (enExample) | ||
| JP2005538737A (ja) | 原核生物ｄｎａを濃縮する方法 | |
| WO2003068268A3 (en) | Treatment, diagnosis and imaging of disease | |
| KR101297309B1 (ko) | 폐암 진단용 조성물 및 폐암 진단키트 | |
| WO2019035763A1 (en) | APTAMERS FOR DETECTION OF ZIKA FLAVIVIRAL PROTEIN | |
| WO2023244680A3 (en) | Reagents and methods for cell identification and characterization | |
| KR101670135B1 (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| CN102140498A (zh) | 体外预测肿瘤转移和侵袭能力的方法及核苷酸片段 | |
| WO2002033084A3 (en) | Identification of the dombrock blood group glycoprotein as a polymorphic member of the adp-ribosyltransferase gene family |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 AUG 2007 |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 13 SEP 2007. |
|
| TH | Corrigenda |
Free format text: IN VOL 20, NO 33, PAGE(S) 3247 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME COMPUGEN USA, INC., APPLICATION NO. 2005320352, UNDER INID (43) CORRECT THE DATE TO 14.12.06 Free format text: IN VOL 20, NO 33, PAGE(S) 3225 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME COMPUGEN USA, INC., APPLICATION NO. 2005320352, UNDER INID (43) CORRECT THE DATE TO 14.12.06 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |